Filing Details

Accession Number:
0000850529-22-000004
Form Type:
13G Filing
Publication Date:
2022-02-06 19:00:00
Filed By:
Fisher Asset Management
Company:
Fisher Asset Management Llc
Filing Date:
2022-02-07
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Fisher Investments 1,104,206 2,268,074 0
Filing

SCHEDULE 13G United States Securities and Exchange Commission Washington, D.C. 20549 Under the Securities Exchange Act of 1934 (Name of Issuer): G1 Therapeutics, Inc. (Title of Class of Securities): Common Stock (CUSIP Number): 3621LQ109 (Date of event which requires filing of this Statement): 11/03/2021 Check the appropriate box to designate the Rule pursuant to which this schedule is filed: [X] Rule 13d-1(b) [ ] Rule l3d-1(c) [ ] Rule l3d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 3621LQ109 (1) Names of Reporting Persons: Fisher Investments (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) N/A (b) N/A (3) SEC Use Only (4) Citizenship or Place of Organization: United States Number of Shares Beneficially Owned By Each Reporting Person With: (5) Sole Voting Power: 1,104,206 (6) Shared Voting Power: N/A (7) Sole Dispositive Power: 2,268,074 (8) Shared Dispositive Power: N/A (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 0 (10) Check if the Aggregate Amount in Row(9) Excludes Certain Shares: No (11) Percent of Class Represented by Amount in Row(9): N/A (12) Type of Reporting Person (See Instructions): IA SCHEDULE 13G Item 1(a). Name of Issuer: G1 Therapeutics, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: G1 Therapeutics, Inc. 700 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 Item 2(a). Name of Person Filing: Fisher Investments Item 2(b). Address of Principal Business Office or, if none, Residence: Fisher Investments 13100 Skyline Blvd. Woodside, CA 94062-4527 Item 2(c). Citizenship: Fisher Investments was incorporated and organized in the state of Delaware, in the United States. Item 2(d). Title of Class of Securities: Common Stock Item 2(e). CUSIP No.: 3621LQ109 Item 3. If this statement is filed pursuant to Rule 13d-l (b) or 13d-2(b), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act (e) [X] Investment Adviser in accordance with 240.13d-1(b) (1)(ii)(E) Item 4. Ownership: Number of Shares: 2,268,074 Percentage of Outstanding Shares: 5.34% Sole Voting Power: 1,104,206 Shared Voting Power: N/A Sole Dispositive Power: 2,268,074 Shared Dispositive Power: N/A Item 5. Ownership of Five Percent or Less of a Class: N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person: N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: N/A Item 8. Identification and Classification of Members of the Group: N/A Item 9. Notice of Dissolution of Group: N/A Item 10. Certification By signing below, I certify that, to the best of my knowledge and belief, the Securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I the Undersigned certify that the information set forth in this statement is true, complete and correct. By: /s/ Tom Fishel Name: Tom Fishel Title: Chief Compliance Officer Date: 02/07/2022